Oncolytics Biotech, Inc. Common Shares earnings per share and revenue
On 12 de nov. de 2025, ONCY reported earnings of -0.14 USD per share (EPS) for Q3 25, missing the estimate of -0.09 USD, resulting in a -43.53% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.85% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analistas forecast an EPS of -0.07 USD, with revenue projected to reach -- USD, implying an diminuir of -50.00% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were Oncolytics Biotech, Inc. Common Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Oncolytics Biotech, Inc. Common Shares reported EPS of -$0.14, missing estimates by -43.53%, and revenue of $0.00, 0% as expectations.
How did the market react to Oncolytics Biotech, Inc. Common Shares's Q3 2025 earnings?
The stock price moved down -4.85%, changed from $1.14 before the earnings release to $1.08 the day after.
When is Oncolytics Biotech, Inc. Common Shares expected to report next?
The next earning report is scheduled for 05 de mar. de 2026.
What are the forecasts for Oncolytics Biotech, Inc. Common Shares's next earnings report?
Based on 4
analistas, Oncolytics Biotech, Inc. Common Shares is expected to report EPS of -$0.07 and revenue of -- for Q4 2025.